Motion Sickness Treatment Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

The motion sickness treatment market size valued for $393.70 million in 2021 and is estimated to reach $525.03 million by 2031, exhibiting a CAGR of 2.9% from 2022 to 2031. Motion sickness, also known as travel sickness or kinetosis, is a condition characterized by a set of symptoms that occur when a person is exposed to motion or movement. It occurs when there is a discrepancy between the sensory information that the eyes, inner ear, and body provide to the brain. The brain receives conflicting information from the eyes and inner ear about the movement and orientation of the body, and this can cause a variety of symptoms such as nausea, vomiting, dizziness, headaches, sweating, and fatigue. It can be caused by various forms of motion, including car rides, airplane flights, boat rides, or even virtual reality experiences.

Motion sickness is more likely to occur in people more prone to it, such as children, pregnant women, and people with a history of migraines. Treatment for motion sickness may include over-the-counter and prescription medications which includes antihistamines, anticholinergics and other medications. The products are available in branded as well as generic form and can be easily accessed through retail and other pharmacies.Major factors that drive the growth of the motion sickness treatment market include increase in incidences of motion sickness, and rise in awareness among the people regarding motion sickness and its treatment options.

In addition, increase in number of travelers is also a major factor contributing toward the market growth. For instance, the World Tourism Organization (UNWTO) stated that more than 900 million tourists travelled internationally in 2022 which was double the number recorded in 2021. This shows a significant increase in the number of travelers, both domestically and internationally. In addition, an article, Motion Sickness: Manifestations and Prevention published by Defence Food Research Laboratory, Mysore stated that, about 5 to 10% of travelers are highly susceptible to motion sickness, while others are moderately susceptible. Thus, it highlights huge incidences of motion sickness among the travelers around the globe, which furthers propels the growth of the motion sickness treatment market.

In addition, major key players are focusing on developing new drugs and APIs that are highly potent and efficient in reducing the symptoms of motion sickness. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug and medications for motion sickness prevention and treatment, which further propels the growth of the market.

On the other hand, lack of awareness about motion sickness and its available treatment in some underdeveloped countries hinder the growth of the market. In addition, some people may be hesitant to use medication to treat motion sickness due to concerns about side effects or a preference for natural remedies. This is projected to limit the demand for motion sickness medications. Moreover, the presence of alternate solutions, such as wearable, for motion sickness may indeed be a hindrance to the market growth. Wearable devices, such as acupressure bands, wristbands, and headsets, have become increasingly popular in recent years as non-pharmaceutical alternatives for managing motion sickness. These factors limit the growth of the market.

However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. These regions are characterized by large populations with high levels of economic growth and increasing disposable incomes. As a result, there is a growing demand for healthcare services, raising awareness for motion sickness treatment medication. Moreover, governments in these regions are increasingly investing in healthcare infrastructure and expanding access to healthcare services, which is further anticipated to augment the market growth.

The motion sickness treatment market is segmented into drug class, route of administration, distribution channel and region. By drugs class, the market is categorized into antihistamines, anticholinergics and others. By route of administration, the market is bifurcated into oral, and others. By distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the motion sickness treatment market include: Prestige Consumer Healthcare Inc., Baxter International Inc., Novartis AG, WellSpring Pharmaceutical Corporation., Amneal Pharmaceuticals LLC., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Viatris Inc., Zydus Cadila and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the motion sickness treatment market analysis from 2021 to 2031 to identify the prevailing motion sickness treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the motion sickness treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global motion sickness treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Antihistamines
Anticholinergics
Others

By Route of Administration

Oral
Others

By Distribution Channel

Drug Store and Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Sun Pharmaceutical Industries Ltd.
Viatris Inc.
Teva Pharmaceutical Industries Limited
Prestige Consumer Healthcare Inc.
Baxter International Inc.
Novartis AG
Amneal Pharmaceuticals LLC
Abbott Laboratories
WellSpring Pharmaceutical Corporation
Zydus Lifesciences Limited

Product Code: A12669

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increasing incidence of motion sickness
  - 3.4.1.2. Surge in adoption of motion sickness treatments
  - 3.4.1.3. Surge in product approval and product launches by the key players

3.4.2. Restraints
- 3.4.2.1. Presence of alternate solution for motion sickness treatment
- 3.4.2.2. Limited awareness and knowledge about motion sickness

3.4.3. Opportunities
- 3.4.3.1. Growth opportunity in emerging markets

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Antihistamines
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Anticholinergics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Others
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: MOTION SICKNESS TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Class
  - 7.2.5.1.3. Market size and forecast, by Route of Administration
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Class
  - 7.2.5.2.3. Market size and forecast, by Route of Administration
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Class
  - 7.2.5.3.3. Market size and forecast, by Route of Administration
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Class
  - 7.3.5.1.3. Market size and forecast, by Route of Administration
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Class
  - 7.3.5.2.3. Market size and forecast, by Route of Administration
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Class
  - 7.3.5.3.3. Market size and forecast, by Route of Administration
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Class
  - 7.3.5.4.3. Market size and forecast, by Route of Administration
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Class
  - 7.3.5.5.3. Market size and forecast, by Route of Administration
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Class
  - 7.3.5.6.3. Market size and forecast, by Route of Administration
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Class
  - 7.4.5.1.3. Market size and forecast, by Route of Administration
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Class
  - 7.4.5.2.3. Market size and forecast, by Route of Administration
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Class
  - 7.4.5.3.3. Market size and forecast, by Route of Administration
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Class
  - 7.4.5.4.3. Market size and forecast, by Route of Administration
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Class
  - 7.4.5.5.3. Market size and forecast, by Route of Administration
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Class
  - 7.4.5.6.3. Market size and forecast, by Route of Administration
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Class
  - 7.5.5.1.3. Market size and forecast, by Route of Administration
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Class
  - 7.5.5.2.3. Market size and forecast, by Route of Administration
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug Class
  - 7.5.5.3.3. Market size and forecast, by Route of Administration
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug Class
  - 7.5.5.4.3. Market size and forecast, by Route of Administration
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Prestige Consumer Healthcare Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Baxter International Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Novartis AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. WellSpring Pharmaceutical Corporation
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Amneal Pharmaceuticals LLC
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Abbott Laboratories
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Viatris Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Limited
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Zydus Lifesciences Limited
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments